Abstract:Significance: Protein neddylation is catalyzed by an E1 NEDD8-activating enzyme (NAE), an E2 NEDD8-conjugating enzyme, and an E3 NEDD8 ligase. Known physiological substrates of neddylation are cullin family members. Cullin neddylation leads to activation of cullin-RING ligases (CRLs), the largest family of E3 ubiquitin ligases responsible for ubiquitylation and degradation of many key signaling/regulatory proteins. Thus, through modulating CRLs, neddylation regulates many biological processes, including cell cycle progression, signal transduction, and tumorigenesis. Given that NEDD8 is overexpressed and CRLs are abnormally activated in many human cancers, targeting protein neddylation, in general, and cullin neddylation, in particular, appears to be an attractive anticancer approach. Recent Advances: MLN4924, a small molecule inhibitor of NAE, was discovered that inactivates CRLs and causes accumulation of CRL substrates to suppress tumor cell growth both in vitro and in vivo. Promising preclinical results advanced MLN4924 to several clinical trials for anticancer therapy. Critical Issues: In preclinical settings, MLN4924 effectively suppresses tumor cell growth by inducing apoptosis, senescence, and autophagy, and causes sensitization to chemoradiation therapies in a cellular context-dependent manner. Signal molecules that determine the cell fate upon MLN4924 treatment, however, remain elusive. Cancer cells develop MLN4924 resistance by selecting target mutations. Future Directions: In the clinical side, several Phase 1b trials are under way to determine the safety and efficacy of MLN4924, acting alone or in combination with conventional chemotherapy, against human solid tumors. In the preclinical side, the efforts are being made to develop additional neddylation inhibitors by targeting NEDD8 E2s and E3s. Antioxid. Redox Signal. 21, 2383-2400.

Phage display to identify Nedd8-mimicking peptides as inhibitors of the Nedd8 transfer cascade.

Profiling the Cross Reactivity of Ubiquitin with the Nedd8 Activating Enzyme by Phage Display.

Neddylation promotes protein translocation between the cytoplasm and nucleus

Discovery of Nedd4 auto-ubiquitination inhibitors

Phage display identification of nanomolar ligands for human NEDD4-WW3: Energetic and dynamic implications for the development of broad-spectrum antivirals

Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway

Next-generation sequencing of a combinatorial peptide phage library screened against ubiquitin identifies peptide aptamers that can inhibit the in vitro ubiquitin transfer cascade

A lysine-to-arginine mutation on NEDD8 markedly reduces the activity of cullin RING E3 ligase through the impairment of neddylation cascades.

Progress in the researches for antitumor NEDD8 activating enzyme inhibitors

Effective Virtual Screening Strategy Toward Covalent Ligands: Identification of Novel NEDD8-Activating Enzyme Inhibitors

NEDD8 Ultimate Buster-1 Long (NUB1L) Protein Promotes Transfer of NEDD8 to Proteasome for Degradation through the P97UFD1/NPL4 Complex

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction.

Gln40 deamidation blocks structural reconfiguration and activation of SCF ubiquitin ligase complex by Nedd8

High‐Throughput Discovery of Substrate Peptide Sequences for E3 Ubiquitin Ligases Using a cDNA Display Method

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

Anticancer Drug Discovery by Targeting Cullin Neddylation

System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes.

Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy

Comparative analysis of the catalytic regulation of NEDD4-1 and WWP2 ubiquitin ligases

Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases